Boston Partners Has $1.95 Million Holdings in Amgen Inc. (AMGN)
Boston Partners cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 25.4% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,326 shares of the medical research company’s stock after selling 3,860 shares during the quarter. Boston Partners’ holdings in Amgen were worth $1,951,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Waldron LP acquired a new stake in shares of Amgen in the first quarter worth $444,000. Moloney Securities Asset Management LLC lifted its stake in shares of Amgen by 23.5% in the first quarter. Moloney Securities Asset Management LLC now owns 8,306 shares of the medical research company’s stock worth $1,363,000 after buying an additional 1,578 shares during the last quarter. KAMES CAPITAL plc lifted its stake in shares of Amgen by 14.7% in the first quarter. KAMES CAPITAL plc now owns 15,023 shares of the medical research company’s stock worth $2,465,000 after buying an additional 1,929 shares during the last quarter. Fulton Breakefield Broenniman LLC lifted its stake in shares of Amgen by 3.1% in the first quarter. Fulton Breakefield Broenniman LLC now owns 40,268 shares of the medical research company’s stock worth $6,607,000 after buying an additional 1,204 shares during the last quarter. Finally, Whittier Trust Co. lifted its stake in shares of Amgen by 2.1% in the first quarter. Whittier Trust Co. now owns 33,660 shares of the medical research company’s stock worth $5,522,000 after buying an additional 700 shares during the last quarter. Hedge funds and other institutional investors own 78.08% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Boston Partners Has $1.95 Million Holdings in Amgen Inc. (AMGN)” was first published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/10/22/boston-partners-has-1-95-million-holdings-in-amgen-inc-amgn.html.
Shares of Amgen Inc. (AMGN) opened at 182.96 on Friday. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $191.10. The company has a market cap of $133.50 billion, a price-to-earnings ratio of 16.66 and a beta of 1.36. The stock has a 50 day moving average of $185.13 and a 200 day moving average of $171.60.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. The business had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. Amgen’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.84 earnings per share. On average, equities analysts expect that Amgen Inc. will post $12.58 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on the stock. BMO Capital Markets cut shares of Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 price objective for the company. in a research note on Friday, July 21st. They noted that the move was a valuation call. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $203.00 price objective (up from $189.00) on shares of Amgen in a research note on Wednesday, July 26th. Royal Bank Of Canada assumed coverage on shares of Amgen in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 price objective for the company. Credit Suisse Group restated a “neutral” rating and issued a $186.00 price objective (up from $177.00) on shares of Amgen in a research note on Friday, September 29th. Finally, Cowen and Company restated an “outperform” rating and issued a $209.00 price objective on shares of Amgen in a research note on Saturday, July 22nd. Twelve analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. Amgen presently has an average rating of “Buy” and an average price target of $189.94.
In related news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $185.95, for a total value of $283,573.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.19% of the stock is owned by insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.